Abstract:Rosmarinic acid (RA), one of the most important polyphenol-based antioxidants, has received growing interest because of its bioactive properties, including anti-inflammatory, anticancer, and antibacterial activities. Despite the high therapeutic potential of RA, its intrinsic properties of poor water solubility and low bioavailability have limited its translation into the clinic. Here, we report on the synthesis and preparation of PEGylated RA-derived nanoparticles (RANPs) and their use as a therapeutic nanomedicine for treatment of inflammatory bowel disease (IBD) in a dextran sulfate sodium (DSS)-induced acute colitis mouse model. PEGylated RA, synthesized via a one-step process from RA and a PEG-containing amine, self-assembled in buffer to form nanoparticles (RANPs) with a diameter of 63.5 ± 4.0 nm. The resulting RANPs showed high colloidal stability in physiological medium up to 2 weeks. RANPs were capable of efficiently scavenging H2O2, thereby protecting cells from H2O2-induced damage. Furthermore, the corticosteroid drug, dexamethasone (DEX), could be loaded into RANPs and released in response to a reactive oxygen species stimulus. Intravenously administered RANPs exhibited significantly improved pharmacokinetic parameters compared with those of the parent RA and were preferentially localized to the inflamed colon. Intravenous administration of RANPs in DSS-induced colitis mice substantially mitigated colonic inflammation in a dose-dependent manner compared with the parent RA, as evidenced by significantly reduced disease activity index scores, body weight loss, and colonic inflammatory damage. In addition, RANPs suppressed expression and production of typical pro-inflammatory cytokines in the inflamed colon. Furthermore, DEX-loaded RANPs showed enhanced therapeutic efficacy in the colitis model compared with bare RANPs at the equivalent dose, indicating synergy with a conventional medication. These findings suggest that RANPs deserve further consideration as a potential therapeutic nanomedicine for the treatment of various inflammatory diseases, including IBD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c01018?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c01018</a>.1H NMR, MALDI-TOF, UV–vis absorbance, FT-IR data of RA, mPEG2k-NH2 and PEG-RA; schematic illustration of RANP formation; zeta potential, mobility, and conductivity values, particle size and stability data of RANPs; changes in the size of RANPs induced by ROS (H2O2) stimulation; schematic illustration of formation, HPLC analysis and particle size distribution data of ; therapeutic effects of RANPs at doses of 50 and 100 mg/kg; comparison of therapeutic effects between RA and RANPs; cross-sectioned H&E images of RANP-treated colons; muscle thickness of colon sections and estimated inflammation score in DSS-induced colitis mice; representative photomicrographs of IHC sections of colons for pSTAT3, NF-kB, and neutrophils; a table for assessment of DAI; a table for assessment of histopathological colitis (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c01018/suppl_file/nn0c01018_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

ROS-responsive nano-medicine for navigating autophagy to enhance targeted therapy of inflammatory bowel disease

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

ROS-responsive Nanoparticles Targeting Inflamed Colon for Synergistic Therapy of Inflammatory Bowel Disease Via Barrier Repair and Anti-Inflammation

ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease

Polycatechol-Derived Mesoporous Polydopamine Nanoparticles for Combined ROS Scavenging and Gene Interference Therapy in Inflammatory Bowel Disease

A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota

Broad-Spectrum Reactive Oxygen Species Scavenging And Activated Macrophage-Targeting Microparticles Ameliorate Inflammatory Bowel Disease

Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis

Reactive oxygen species-scavenging hollow MnO2 nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy

A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease

Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease

Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease

A Biomimetic Nanoplatform with Improved Inflammatory Targeting Behavior for ROS Scavenging‐Based Treatment of Ulcerative Colitis

Enzyme/ROS dual-sensitive nanoplatform with on-demand Celastrol release capacity for enhanced ulcerative colitis therapy by ROS scavenging, microbiota rebalancing, inflammation alleviating

Sulfasalazine-loaded nanoparticles for efficient inflammatory bowel disease therapy via ROS-scavenging strategy

Reactive Oxygen Species‐Activated CO Versatile Nanomedicine with Innate Gut Immune and Microbiome Remodeling Effects for Treating Inflammatory Bowel Disease

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis

Metabolic Nanoregulator Remodels Gut Microenvironment for Treatment of Inflammatory Bowel Disease

pH and ROS Dual-Sensitive Nanocarriers for the Targeted Co-Delivery and On-Demand Sequential Release of Tofacitinib and Glucosamine for Synergistic Rheumatoid Arthritis Treatment

Orally Deliverable Microalgal-Based Carrier with Selenium Nanozymes for Alleviation of Inflammatory Bowel Disease